Quality-of-life (QoL) assessments in patients (pts) with pancreatic neuroendocrine tumors (pNET) enrolled in the open-label, phase 3b, multicenter, expanded access study of everolimus in pts with advanced NET

EUROPEAN JOURNAL OF CANCER(2013)

Cited 0|Views6
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined